P-0046 - Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy
|Date||28 June 2014|
|Event||World GI 2014|
|Citation||Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165|
K. Fujitani1, T. Tsuji2, K. Inoue3, K. Kobayashi4
We have already reported the superior feasibility and safety and 3-year outcomes of adjuvant S-1 plus docetaxel in patients with stage III gastric cancer as a prospective phase II study. We report 5-year follow-up data on patients enrolled onto this study.
Fifty-three patients with histologically confirmed stage III gastric cancer who underwent gastrectomy with D2 lymph-node dissection were enrolled into this study. They received oral S-1 (80 mg/m2/day) administration for 2 weeks and intravenous docetaxel (40 mg/m2) on day 1, repeated every 3 weeks (1 cycle). This treatment was started within 45 days after surgery and repeated for 4 cycles, followed by S-1 monotherapy (4 weeks on, 2 weeks off) until 1 year after surgery. Five-year overall survival (OS) and disease-free survival (DFS) were evaluated.
The OS rate at 5 years was 68.3% (95%CI, 54.2% to 85.6%) and the DFS rate at 5 years was 62.4% (95% CI, 50.4% to 77.3%). Subgroup analyses according to the stage showed 5-year OS and DFS of 73.9% (95%CI, 60.4% to 90.1%) and 68.1% (95%CI, 54.2% to 85.6%) for stage IIIA, and 56.2% (95% CI, 36.5% to 86.7%) and 50.0% (95% CI, 30.6% to 81.6%) for stage IIIB.
On the basis of 5-year follow up data, postoperative adjuvant therapy with S-1 plus docetaxel yielded promising OS and DFS in stage III gastric cancer patients who underwent gastrectomy with D2 lymph-node dissection. We believe that this regimen will be a candidate for future phase III trials seeking the optimal adjuvant chemotherapy for stage III gastric cancer.